### Index

*Note:Italicised f and t refer to figures and tables.*

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>acetaminophen, 173</td>
</tr>
<tr>
<td>acupuncture, 153</td>
</tr>
<tr>
<td>adnexal masses, 195–8</td>
</tr>
<tr>
<td>afferent excitation, 140</td>
</tr>
<tr>
<td>agonists, 178</td>
</tr>
<tr>
<td>Alcock's canal, 19</td>
</tr>
<tr>
<td>allergic contact dermatitis, 52–3</td>
</tr>
<tr>
<td>amitriptyline, 78, 90, 159, 172</td>
</tr>
<tr>
<td>anal sphincter tears, 227</td>
</tr>
<tr>
<td>anastrozole, 220</td>
</tr>
<tr>
<td>androgen insensitivity syndrome (AIS), 122</td>
</tr>
<tr>
<td>androgenic steroids, 197</td>
</tr>
<tr>
<td>androgens, 182–4</td>
</tr>
<tr>
<td>clinical data, 184</td>
</tr>
<tr>
<td>pathophysiology of, 182–3</td>
</tr>
<tr>
<td>physiology, 182–3</td>
</tr>
<tr>
<td>anesthetics, 157, 159</td>
</tr>
<tr>
<td>animal models, of dyspareunia, 199–205</td>
</tr>
<tr>
<td>colitis, 203–4</td>
</tr>
<tr>
<td>common pain behaviors, 201f</td>
</tr>
<tr>
<td>endometriosis, 202–3</td>
</tr>
<tr>
<td>evaluation of, 199–200</td>
</tr>
<tr>
<td>interstitial cystitis, 203</td>
</tr>
<tr>
<td>parturition, 203–4</td>
</tr>
<tr>
<td>urethral calculus, 200</td>
</tr>
<tr>
<td>uterine distension, 202</td>
</tr>
<tr>
<td>uterine inflammation, 200–202</td>
</tr>
<tr>
<td>vaginal distension, 202</td>
</tr>
<tr>
<td>validity of, 204–5</td>
</tr>
<tr>
<td>yeast-induced sensitization to touch, 204</td>
</tr>
<tr>
<td>antagonists, 178</td>
</tr>
<tr>
<td>anterior separation, 144</td>
</tr>
<tr>
<td>antibiotics, 15, 70–71</td>
</tr>
<tr>
<td>antidepressants, 78</td>
</tr>
<tr>
<td>antiprogestins, 197</td>
</tr>
<tr>
<td>aphthous ulcers, 35–6, 54</td>
</tr>
<tr>
<td>aromatase inhibitors, 220</td>
</tr>
<tr>
<td>atrophic vaginitis, 105–7. See also desquamative inflammatory vaginitis (DIV)</td>
</tr>
<tr>
<td>diagnosis of, 106–7</td>
</tr>
<tr>
<td>etiology of, 105</td>
</tr>
<tr>
<td>hormonal factors in, 187–9</td>
</tr>
<tr>
<td>sexual dysfunction in, 105–6</td>
</tr>
<tr>
<td>treatment of, 107</td>
</tr>
<tr>
<td>atrophic vulvovaginitis, 38</td>
</tr>
<tr>
<td>baclofen, 159</td>
</tr>
<tr>
<td>bacterial vaginosis, 95–8</td>
</tr>
<tr>
<td>clinical features of, 96–7</td>
</tr>
<tr>
<td>diagnosis of, 97</td>
</tr>
<tr>
<td>epidemiology, 95–6</td>
</tr>
<tr>
<td>management of, 97–8</td>
</tr>
<tr>
<td>pathogenesis, 96</td>
</tr>
<tr>
<td>vulvovaginal candidiasis, 99–102</td>
</tr>
<tr>
<td>Bartholin glands, 18</td>
</tr>
<tr>
<td>Beck Anxiety Inventory (BAI), 23</td>
</tr>
<tr>
<td>Beck Depression Inventory II (BDI-II), 23</td>
</tr>
<tr>
<td>Behcets disease, 54</td>
</tr>
<tr>
<td>benzocaine, 157</td>
</tr>
<tr>
<td>biofeedback, 11, 79, 153</td>
</tr>
<tr>
<td>The Body Human (television show), 253</td>
</tr>
<tr>
<td>botulinum toxin, 159–60</td>
</tr>
<tr>
<td>brain–gut interactions, 139–40</td>
</tr>
<tr>
<td>breast cancer patients, 220</td>
</tr>
<tr>
<td>Burch procedure, 144</td>
</tr>
<tr>
<td>burning vulva syndrome. See vulvodynia</td>
</tr>
<tr>
<td>butoconazole, 102f</td>
</tr>
<tr>
<td>The Camera My Mother Gave Me (book), 253</td>
</tr>
<tr>
<td>cancer patients, 218–21</td>
</tr>
<tr>
<td>cancer-related sexual pain, 221</td>
</tr>
<tr>
<td>evaluation of, 219</td>
</tr>
<tr>
<td>local issues, 220</td>
</tr>
<tr>
<td>multimodal therapeutic management, 221–2</td>
</tr>
<tr>
<td>physical examination of, 219</td>
</tr>
<tr>
<td>sexual dysfunction in, 219–20</td>
</tr>
<tr>
<td>sexual history of, 218–9</td>
</tr>
<tr>
<td>systemic issues, 220–21</td>
</tr>
<tr>
<td>Candida, 99–101</td>
</tr>
<tr>
<td>candidiasis, vulvovaginal, 99–102</td>
</tr>
<tr>
<td>clinical features of, 100–101</td>
</tr>
<tr>
<td>diagnosis of, 101</td>
</tr>
<tr>
<td>epidemiology, 99</td>
</tr>
<tr>
<td>host factors, 100</td>
</tr>
<tr>
<td>management of, 101</td>
</tr>
<tr>
<td>pathogenesis of, 99–100</td>
</tr>
<tr>
<td>treatment of, 101–2</td>
</tr>
<tr>
<td>cannabinoids, 173, 259</td>
</tr>
<tr>
<td>capsaicin, 157–8</td>
</tr>
<tr>
<td>carbamazepine, 173</td>
</tr>
<tr>
<td>cefotetan, 71f</td>
</tr>
<tr>
<td>cefoxitin, 71f</td>
</tr>
<tr>
<td>ceftiraxone, 71f</td>
</tr>
<tr>
<td>cephalosporin, 71f</td>
</tr>
<tr>
<td>Cesamet, 173</td>
</tr>
<tr>
<td>chancroid, 68</td>
</tr>
<tr>
<td>Changes in Sexual Functioning Questionnaire (CSFQ), 23</td>
</tr>
<tr>
<td>childbirth, 224</td>
</tr>
<tr>
<td>childhood sexual abuse, 139</td>
</tr>
<tr>
<td>Chlamydia trachomatis, 68–9, 72</td>
</tr>
<tr>
<td>chronic pelvic pain (CPP), 72</td>
</tr>
<tr>
<td>and dyspareunia, 9</td>
</tr>
<tr>
<td>in irritable bowel syndrome, 138–9</td>
</tr>
<tr>
<td>and sexual abuse, 139, 213–4</td>
</tr>
<tr>
<td>chronic vulvar pain. See vulvodynia</td>
</tr>
<tr>
<td>chronic vulvovaginal candidiasis, 38</td>
</tr>
<tr>
<td>clindamycin, 71f</td>
</tr>
</tbody>
</table>
clinical interview, 21–2
clitoridectomy, 236
clitoris, 120, 181
clotrimazole, 102
codeine, 173
cognitive behavioral therapy (CBT), 150–53
colitis, 203–4
combined oral contraceptives (COCs), 127
cone snail research, 259
congenital adrenal hyperplasia (CAH), 122
contact dermatitis, 52–3
contraceptives, 15
Coopers ligament, palpation of, 144
corticosteroids, 158–9
cotton swab test, 18
Crohns disease, 36
Cushings disease, 183
cyclooxygenase-2 (COX-2), 133
Cymbalta, 78
cystourethroceles, 144
Danazol, 127
dep deep dyspareunia, 72
dehydroepiandrosterone (DHEA), 180, 182–4
Depo-Lupron, 197
dermatologic assessment, 246
dermatoses, vulvar, 49–55
aphthous ulcers, 54
Behcets disease, 54
contact dermatitis, 52–3
lichen planus, 51–2
lichen sclerosis, 50–51
lichen simplex chronicus, 53–4
mucous membrane pemphigoid, 54–5
overview, 49
plasma cell vulvitis, 55
vulvar examination, 49–50
desipramine, 78
desquamative inflammatory vaginitis (DIV), 107–10.
See also atrophic vaginitis
diagnosis of, 109
epidemiology, 108
etiology of, 108–9
microscopic findings in, 109f
overview of, 108–9
treatment of, 109–10
disinhibition, 140
docosahexaenoic acid (DHA), 132
Doxepin, 159
doxycycline, 71
 duloxetine, 78, 173
Dyadic Adjustment Scale (DAS), 23
animal models of, 199–205
colitis, 203–4
common pain behaviors, 201
endometriosis, 202–3
evaluation of, 199–200
interstitial cystitis, 203
parturition, 203–4
ureteral calculosis, 200
uterine distension, 202
uterine inflammation, 200–202
vaginal distension, 202
validity of, 204–5
yeast-induced sensitization to touch, 204
assessment of, 5
in cancer patients, 218–22
and congenital anomalies of female genital tract, 119–22
definitions of, 4, 9
evaluation of, 14–20
medical history, 14–15
medication history, 15–17
physical exam, 17–18, 28–30
physical therapy, 27–31
testing, 19–20
and female sexual dysfunction, 6, 92f
and fibroids, 196–7
as individual and societal burden, 9–10
infections in, 10
and interstitial cystitis, 88–92
multidisciplinary treatment of, 10–11
new assessment and treatment, 11–12
outcome issues, 11
and ovarian mass, 196
postpartum, 224–7
anal sphincter tears, 227
generalized pain, 226
localized pain, 226
minimizing trauma in, 227
overview, 224
and perineal trauma, 224–5
physical therapy, 226
prevention of, 226
repair techniques, 226
TENS unit therapy, 226
treatment of, 226–7
ultrasound, 226
prevalence of, 4–7
psychological aspects of, 209–10
psychological evaluation of, 21–4
clinical interview, 21–2
quantifiable measures, 23–4
self-administered measures, 22–3
relationship aspects of, 209
and sexual abuse, 213–6
sexual aspects of, 208–9
sexual distress in, 5–6
study design, 4–5
and vaginismus, 229
and vaginitis, 95
vulvar dermatoses in, 49–55
in vulvodynia, 2
econazole, 102
Effexor XR, 78
Elavil, 78, 159
endometriosis, 124–8
animal model, 202–3
diagnosis of, 126
epidemiology of, 125
etiology of, 124–5
history of, 126
imaging studies, 126
laparoscopy, 126
medical treatment of, 127
overview of, 124
physical examination of, 126
surgical treatment of, 127–8
estradiol, 184
estrogens, 184–5
clinical data, 185
pathophysiology of, 184–5
physiology of, 184–5
topical, 158
female genital cutting, 235–42
culturally competent care, 240–42
epidemiology, 235–6
female genital cutting (cont.)
- medical outcomes, 236
- neurobiological outcomes, 236–7
- overview, 235
- psychosocial outcomes, 236–7
- surgical management, 237–40
- types of, 235, 236
female genital tract, 119–22
- congenital anomalies of, 119–22
  - clitoris, 120
  - vagina, 120–22
  - vulva, 120
- early development of, 119
- genetic and chromosomal abnormalities, 122
female sexual arousal disorder (FSAD), 15
Female Sexual Distress Scale (FSDS), 23, 90
female sexual dysfunction (FSD), 91–2
- and dyspareunia, 6
- in irritable bowel syndrome, 137–8
- and sexual abuse, 139
Female Sexual Function Index (FSFI), 23
fentanyl patch, 173
fenticonazole, 102
fibroblast cell culture research, 259
fibroids
- and dyspareunia, 196–7
- treatment of, 197
Fitz Hugh Curtis syndrome, 132
flucnconazole, 102
functional magnetic resonance imaging, 259
gabapentin, 79, 158, 172–3
Gardnerella vaginalis, 96
generalized vulvodynia (GVD), 76–80
epidemiology, 76
etiology of, 76–7
overview of, 76
physical examination of, 77
- treatment of, 77–80
biofeedback, 79
injectable therapies, 79
oral treatments, 78–9
physical therapy, 79
psychological aspects, 79–80
- topical treatment, 77–8
- genital examination, 29–30
- genital herpes, 66–8. See also sexually transmitted infections (STIs)
- clinical presentations, 66–7
- diagnostic testing of, 68
- treatment of, 68
- virology, 66
- gentamicin, 71
- Glazer protocol, 30
- Golombok Rust Inventory of Sexual Satisfaction (GRISS), 23
- gonadotropin-releasing hormone agonists (GnRHa), 127
- Graves speculum, 18
- group cognitive-behavioral therapy (GCBT), 11–12
Harts line, 18
herpes, 66–8. See also sexually transmitted infections (STIs)
- clinical presentations, 66–7
- diagnostic testing of, 68
- treatment of, 68
- virology, 66
- herpes simplex virus (HSV), 35, 66
- hidradenitis suppurativa (HS), 57–63
- diagnosis of, 58–60
- epidemiology, 57–8
- historical background, 57
- overview of, 57
- treatment of, 60–63
- medical therapy, 60–61
- psychosocial issues, 61–3
- surgical management, 61
histology, 19
HIV positive patients, 71
hormonal therapies, 197
human papillomavirus (HPV), 159
hydromorphone, 173
hydroxyzine, 90
hyperprolactinemia, 183
hynopsis, 153
hyposexual sexual desire disorder (HSDD), 15
IMMPACT group, 256
infection assessment, 246–7
injectable therapy, 159–60
anesthetics, 159
botulinum toxin, 159–60
corticosteroids, 159
interferon, 159
interferon, 159
International Society for the Study of Vulvovaginal Disease (ISSVD), 255
interstitial cystitis, 203
Interstitial Cystitis Association (ICA), 253
interstitial cystitis/painful bladder syndrome (IC/PBS), 88–92
diagnosis of, 88–90
etiology of, 88
overview, 88
and sexual dysfunction, 91–2
- treatment of, 90–91
intrauterine devices (IUDs), 71
invasive vulvar cancer, 39
irritable bowel syndrome (IBS), 136–42
brain gut interactions, 139–40
chronic pelvic pain in, 138–9
comorbid conditions and symptoms, 137
conceptual model, 140
- overview, 136–7
- Rome III diagnostic criteria for, 137
- and sexual abuse, 214–5
- sexual dysfunction in, 137–9
- irritant contact dermatitis, 52–3
- itraconazole, 102
ketoconazole, 102
labia majora, 17
labia minora, 18
lamotrigine, 173
leiomymata, 196
laser-evoked potentials, 258
leiomyomata, 196
lichen planus, 37–8, 51–2, 146
lichen sclerosus, 36–7, 50–51
lichen simplex chronicus (LSC), 37–8, 53–4, 146
lidocaine, 78, 157, 159, 173
leiomymomas, 195–8
Locke Wallace Marital Adjustment Test (LWMAT), 23
Lyrica, 79
mast cells, 176–8
  clinical significance of, 178
  functional role of, 177–8
  inflammatory response, 177
  neovascularization, 177–8
  neurogenic inflammation, 177
  neurogenic response, 177
  re-epithelialization, 177–8
  scarring, 178
  vascular response, 177
importance of, 176
morphology of, 176–7
overview of, 176
Mayer Rookitansky Kuster Hauser (MRKH) syndrome, 121
McCoy Female Sexuality Questionnaire (MFSQ), 23
McGill Pain Questionnaire, 1
McGill Melzack Pain Questionnaire (MPQ), 22
medical history, 14–15, 28
Medical Research Fund, 252
medications, and dyspareunia, 15–17
Medoc Thermal Genital Sensory Analyzer, 24
Medoc Vibratory Sensory Analyzer, 24
meperidine, 173
methadone, 173
methylprednisolone, 159
metronidazole, 71
miconazole, 102
mifepristone, 197
Mirena IUD, 197
Mittleshmertz, 196
modified vestibulectomy, 162
morphine, 173
mucous membrane pemphigoid, 54–5
Müllerian duct, 119
muscle assessment, 246
musculoskeletal exam, 29
myofascial trigger point release, 83
National Institutes of Health (NIH), 251–2, 256
National Vulvodynia Association (NVA), 250–54
advocates, 254
career development award, 252
educational information, 250
healthcare provider referrals, 251
lobbying for research funding, 251–2
medical research fund, 252
online support, 250–51
partners, 254
professional education, 252–3
public awareness campaign, 253–4
support network, 250–51
Neisseria gonorrhoea, 69, 72
neovascularization, 177–8
neuralgia, pudendal, 112–6
anatomy of, 112–4
clinical features of, 112–6
diagnosis of, 114–5
etiology of, 114
modification of activities in, 115
neurophysiologic testing, 114
overview, 112
pharmacological measures, 115
physical therapy treatment of, 115–6
pudendal nerve block, 114–6
pudendal nerve decompression, 116
neurogenic inflammation, 177
neurological assessment, 247
Neurontin, 79
nitroglycerin, 158
noninfectious vaginitis, 105–10
atrophic, 105–7
diagnosis of, 106–7
etiology of, 105
sexual dysfunction in, 105–6
treatment of, 107
desquamative inflammatory, 107–10
diagnosis of, 109
epidemiology, 108
etiology of, 108–9
microscopic findings in, 109f
overview of, 108–9
treatment of, 109–10
treatment of, 102–3
Norpramin, 78
nortriptyline, 78, 90, 172
nysatin, 102
Office of Research on Women’s Health (ORWH), 252
OLeary Sant Symptom and Problem Index (OSSOI), 89–90
opioids, 173
oral contraceptives, 15, 69, 197
ovarian masses, 195–6
ovarian suppression, 220
ovulatory pain, 196
oxycodone, 173
pain, 199–200. See also dyspareunia
animal models of, 199–205
colitis, 203–4
common pain behaviors, 201
endometriosis, 202–3
evaluation of, 199–200
interstitial cystitis, 203
parturition, 203–4
urethral calculus, 200
uterine distension, 202
uterine inflammation, 200–202
vaginal distension, 202
validity of, 204–5
yeast-induced sensitization to touch, 204
injectable therapy, 158–60
anesthetics, 159
benefit of, 156
botulinum toxin, 159–60
corticosteroids, 158–9
interferon, 159
side effects and limitations, 157
interference and comorbid problems, 21–2
mediators, 21
in pelvic floor dysfunction, 160
properties, 21
self-administered measures, 22–3
topical therapy, 156–9
anesthetics, 157
benefit of, 156
capsaicin, 157–8
drug trials, 157
estrogen, 158
gabapentin, 158
nitroglycerin, 158
side effects and limitations, 157
testosterone, 158
tricyclic antidepressants, 158
pain, vulvar, 169–74. See also dyspareunia
classification, 170
injectable therapy, 158–60
anesthetics, 159
benefit of, 156
botulinum toxin, 159–60
corticosteroids, 159
interferon, 159
side effects and limitations, 157
overview, 169
pain management, 170–74
in pelvic floor dysfunction, 160
topical therapy, 156–9
anesthetics, 157
benefit of, 156
capsaicin, 157–8
drug trials, 157
estrogen, 158
side effects and limitations, 157
testosterone, 158
pain behaviors, 201
Pain Catastrophizing Scale (PCS), 22
pelvic center, sexual, 244–50
all-inclusive model, 248
assessment and diagnostic testing, 246–7
cash payment model, 247
categories of pain etiologies, 244
coordinating treatment in, 247
goals, 244–5
insurance model, 247–8
integrated approach, 245–6
mission statement, 244
patient convenience items, 248
physical setting, 246
reimbursement and coding in, 247–8
support services, 245
team leaders, 245
team members, 245
painful bladder syndrome (PBS), 88–92
diagnosis of, 88–90
etiology of, 88
overview, 88
and sexual dysfunction, 91–2
treatment of, 90–91
Pamelor, 78
parturition, 203–4
patient advocacy, 250–54
pelvic anatomy, 27–8
pelvic floor, 30
electromyographic assessment of, 30
examination of, 30
musculature, 30
pelvic floor dysfunction (PFD), 19
pain in, 160
physical therapy treatment of, 82–6
joint mobilization, 84
myofascial trigger point release, 83
neural mobilization, 83–4
therapeutic exercises, 84–5
visceral manipulation, 83
pelvic floor rehabilitation, 150–53
pelvic inflammatory disease (PID), 131–4. See also sexually transmitted infections (STIs)
causes of, 69
clinical features of, 70
diagnosis of, 69–70, 133–4
differential diagnosis of, 70
in HIV positive patients, 71
incidence of, 69
laparoscopy, 70
long-term complications, 72
chronic pelvic pain, 72
deep dyspareunia, 72
follow-up, 72
prevention, 72
tubal infertility, 72
management of, 133–4
antibiotics, 70–71
outcomes/complications, 71–2
partner notification, 71
removal of IUDs, 71
pelvic adhesions, 131–3
pelvic pain in, 131–3
and pregnancy, 71
prevention of, 133
symptoms of, 70
tests, 70
pelvic organ prolapse (POP), 143–8
anterior defects, 144
diagnosis of, 143–4
overview, 143
posterior defects, 145–6
mucosal factors, 145–6
parturition, 145
perineum, 145
uterine prolapse, 147
vulvar effects of, 146–7
cervical discharge, 146–7
incontinence, 146
perineal disruption, 146
prolapse, 146–7
Pelvic Pain and Urgency/Frequency Scale (PUF), 89
pentosanpolysulfate sodium (PPS), 90
perineal region, normal anatomy of, 181
physical therapy, 79
pelvic therapy treatment, 82–6
behavioral therapies, 85
joint mobilization, 84
myofascial trigger point release, 83
neural mobilization, 83–4
therapeutic exercises, 84–5
visceral manipulation, 83
PID Evaluation and Clinical Health (PEACH) study, 132
plasma cell vulvitis, 55
postpartum dyspareunia, 224–7. See also dyspareunia
minimizing trauma in, 227
overview, 224
and perineal trauma, 224–5
prevention of, 226
repair techniques, 226
treatment of, 226–7
anal sphincter tears, 227
generalized pain, 226
localized pain, 226
physical therapy, 226
TENS unit therapy, 226
ultrasound, 226
posture, 28–9
potassium hydroxide (KOH) prep, 19
potassium sensitivity test (PST), 90
pregabalin, 79, 172
pregnancy, and pelvic inflammatory disease, 71
pressure pain measurement, 23–4
Private Practice (television show), 253
progesterone, 185
progestins, 127
provoked vestibulodynia (PVD), 43–7
causes of, 45–7
acquired neuronal proliferation, 46t
congenital neuronal hyperplasia, 47t
hormonal changes, 46t
erythema of, 18f
etiology of, 43–5
evaluation of, 45
hormonal factors in, 185–7
medical treatment of, 45–6
multidisciplinary treatment of, 47
pathophysiology of, 162
surgical therapy, 162–7
complications, 165
effect of patient selection, 165
overview of, 46–7
postoperative care, 164–5
study design, 167
success factors, 165–6
surgeal outcomes, 165–6
surgical technique, 162–4
vulvar vestibule, 43
provoked vulvodynia, 2
pseudohermaphroditism, 122
psycho-behavioral assessment, 246
psychological distress, 209–10
psychotherapy, 150–53
psychoactive drugs, 15
pudendal nerve block, 115–6
pudendal neuralgia, 112–6
anatomy of, 112–4
clinical features of, 112–6
diagnosis of, 114–5
etiology of, 114
modification of activities in, 115
neurophysiologic testing, 114
overview, 112
pharmacological measures, 115
physical therapy treatment of, 115–6
pudendal nerve block, 114–6
pudendal nerve decompression, 116
Q-tip test, 144
quantitative sensory testing (QST), 23–4, 257, 258
random controlled trials (RCTs), 256–8
re-epithelialization, 177–8
relationship adjustment, 22
relationships and dyspareunia, 209
research, 255–9
basic research, 258
comorbidity studies, 258
diagnostic categories, 255, 258–9
epidemiological research, 256
fibroblast cell culture, 258–9
laser-evoked potentials, 258
QST profiling, 258
random controlled trials, 256–8
sexual dysfunction and relationships, 258
sexual distress, 5–6
treatment, 259
Sativex, 173
scarring, 178
Schwann cells, 259
selective norepinephrine reuptake inhibitors (SNRIs), 78, 173
selective serotonin reuptake inhibitors (SSRIs), 78, 173
self-administered measures, 22–3
pain, 22
psychological function, 23
relationship adjustment, 23
sexual function, 22–3
semen testing, 19–20
Sex and the City (television show), 253
sex hormone binding globulin (SHBG), 19–20
sex steroids, clinical measurement of, 180–82
sexual abuse, 213–6
sexual distress, 5–6
and chronic pelvic pain, 213–4
factors in, 215
and irritable bowel syndrome, 139, 214–5
overview of, 213
and pain, 215–6
and urinary symptoms, 215
and vulvodynia, 215
sexual function, 91–2
in cancer patients, 219–20
in irritable bowel syndrome, 137–9
and relationships, 258
in vaginal atrophy, 105–6
Sexual Function Questionnaire (SFQ), 23
sexual pain center, 244–50
all-inclusive model, 248
assessment and diagnostic testing, 246–7
cash payment model, 247
categories of pain etiologies, 244
coordinating treatment in, 247
diagnostic codes, 248
goals, 244–5
insurance model, 247–8
integrated approach, 245–6
mission statement, 244
patient convenience items, 248
physical setting, 246
procedure codes, 248
reimbursement and coding in, 247–8
support services, 245
team leaders, 245
team members, 245
sexual pain disorders, 185–9
atrophic vaginitis, 187–9
in cancer patients, 218–22
hormonal factors in, 180–89
provoked vestibulodynia, 185–7
sexual pain history, 16t
Sexual Satisfaction Scale for Women (SSS-W), 23
sexually transmitted infections (STIs), 66–72
chancroid, 68
genital herpes, 66–8
lymphogranuloma venereum, 68
overview of, 66–72
pelvic inflammatory disease, 69–72
syphilis, 68
trichomoniasis, 68–9
siRNA targeting, 259
Skene glands, 18
surgical therapy, 162–7
  complications, 165
  effect of patient selection, 165
  outcomes, 165–6
  postoperative care, 164–5
  study design, 167
  success factors, 165–6
  success rates, 166
  techniques, 162–4
  vestibulectomy, 162
  vestibuloplasty, 162
syphilis, 68
systematically acting agents, 259
systemic therapy, 220–21
tamoxifen, 220
terconazole, 102
testosterone, 158
tioconazole, 102
toluidine blue test (TBT), 32
topical drugs, 78–9
topical therapy, 156–9
  anesthetics, 157
  benefit of, 156
  capsaicin, 157–8
  drug trials, 157
  estrogen, 158
  gabapentin, 158
  nitroglycerin, 158
  side effects and limitations, 157
  testosterone, 158
  tricyclic antidepressants, 158
tramadol, 173
transcutaneous electrical stimulations (TENS), 226
trichomoniais, 98–9
  clinical features of, 98
  diagnosis of, 98–9
  epidemiology, 98
  management of, 99
  pathophysiology of, 98
Trichomoniasis vaginialis, 68
tricyclic antidepressants (TCAs), 78, 158, 172
tubal infertility, 72
Turner syndrome, 122
ulcerative conditions, 34–40
  aphthous ulcers, 35–6
  atrophic vulvovaginitis, 38
  chronic vulvovaginal candidiasis, 38
  Crohn’s disease, 36
  herpes simplex virus, 35
  invasive vulvar cancer, 39
  lichen planus, 37
  lichen sclerosus, 36–7
  lichen simplex chronicus, 37–8
  vulvar intraepithelial neoplasia, 38–9
  vulvar Paget’s disease, 39–40
ultrasound therapy, 226
urethral meatus, normal anatomy of, 226
urinary symptoms, 215
uterine distension, 202
uterine inflammation, 200–202
uterine leiomyomata, 196
uterine prolapse, 147

The VB Book, 253
vagina, 120–22
  vaginal atrophy, 105–6
  etiology of, 105
  sexual dysfunction in, 105–6
  vaginal delivery, 145
vaginal distension, 202
vaginal distension, 202
vaginismus, 229–32
  anxiety in, 230
  definitions of, 229
  and dyspareunia, 229
  etiology of, 230–31
  symptoms, 229
  treatment of, 231–2
  vicious cycle of, 231f
vaginitis, 105–10
  atrophic, 105–7
  diagnosis of, 106–7
  etiology of, 105
  sexual dysfunction in, 105–6
  treatment of, 107
  desquamative inflammatory, 107–10
  diagnosis of, 109
  epidemiology, 108
  etiology of, 108–9
  microscopic findings in, 109f
  overview of, 108–9
  treatment of, 109–10
  noninfectious, 102–3, 105–10
vaginosis, bacterial, 95–8
  clinical features of, 96–7
  diagnosis of, 97
  epidemiology, 95–6
  management of, 97–8
  pathogenesis, 96
  vulvovaginal candidiasis, 99–102
Vagisil, 157
venlafaxine, 78, 173
vestibulectomy, 162
vestibulodynia, provoked, 43–7
  causes of, 45–7
  acquired neuronal proliferation, 46t
  congenital neuronal hyperplasia, 47t
  hormonal changes, 46t
  pelvic floor dysfunction, 45r
  etiology of, 43–5
  evaluation of, 45
  hormonal factors in, 185–7
  medical treatment of, 45–6
  multidisciplinary treatment of, 47
  pathophysiology of, 162
  surgery for, 46–7
  surgical therapy, 162–7
  complications, 165
  effect of patient selection, 165
  postoperative care, 164–5
  study design, 167
  success factors, 165–6
  surgical outcomes, 165
  surgical procedures, 162
  surgical technique, 162–4
  vulvar vestibule, 43
vestibuloplasty, 162
video colposcope, 17
visceral manipulation, 83
vulva, 120
  anatomy of, 17f, 44f
  congenital anomalies, 120
  physical examination of, 49–50
  sensory exam of, 17
  ulcerative conditions, 34–40
  aphthous ulcers, 35–6
  atrophic vulvovaginitis, 38
chronic vulvovaginal candidiasis, 38
Crohn’s disease, 36
herpes simplex virus, 35
invasive vulvar cancer, 39
lichen planus, 37
lichen sclerosis, 36–7
lichen simplex chronicus, 37–8
vulvar intraepithelial neoplasia, 38–9
vulvar Paget’s disease, 39–40
vulvovagiosiometer, 24
vulvar dermatoses, 49–55
aphthous ulcers, 54
Behcet’s disease, 54
contact dermatitis, 52–3
lichen planus, 51–2
lichen sclerosis, 50–51
lichen simplex chronicus, 53–4
mucous membrane pemphigoid, 54–5
overview, 49
plasma cell vulvitis, 55
vulvar examination, 49–50
vulvar intraepithelial neoplasia (VIN), 38–9
vulvar Paget’s disease, 39–40
vulvar pain, 169–74. See also dyspareunia
classification, 170r
injectable therapy, 159–60
anesthetics, 159
benefit of, 156
botulinum toxin, 159–60
corticosteroids, 158–9
interferon, 159
side effects and limitations, 157
management of, 170–74
overview, 169
in pelvic floor dysfunction, 160
topical therapy, 156–9
anesthetics, 157
benefit of, 156
capsaicin, 157–8
drug trials, 157
estrogen, 158
gabapentin, 158
nitroglycerin, 158
side effects and limitations, 157
testosterone, 158
vulvar vestibectomy, 162
vulvar vestibulitis syndrome (VVS), 1–2
vulvitis, 102–3
vulvodynia, 1–3
vs chronic vulvar pain, 2–3
generalized, 76–80
biofeedback, 79
epidemiology, 76
etiology of, 76–7
history of term, 2
injectable therapies, 79
oral treatments, 78–9
overview of, 76
physical examination of, 77
physical therapy, 79
psychological aspects, 79–80
topical treatment, 77–8
history of, 1
major subtypes, 2
provoked vestibulodynia, 1
and sexual abuse, 215
treatment of, 150–53
acupuncture, 153
biofeedback, 153
cognitive behavioral therapy, 150–53
hypnosis, 153
pelvic floor rehabilitation, 150–53
psychotherapy, 150–53
vulvoscopy, 32–41
findings, 33–40
aphthous ulcers, 35–6
atrophic vulvovaginitis, 38
chronic vulvovaginal candidiasis, 38
Crohn’s disease, 36
herpes simplex virus, 35
invasive vulvar cancer, 39
lichen planus, 37
lichen sclerosis, 36–7
lichen simplex chronicus, 37–8
vulvar intraepithelial neoplasia, 38–9
vulvar Paget’s disease, 39–40
vulvar pain, 169–74. See also dyspareunia
classification, 170r
injectable therapy, 159–60
anesthetics, 159
benefit of, 156
botulinum toxin, 159–60
corticosteroids, 158–9
interferon, 159
side effects and limitations, 157
management of, 170–74
overview, 169
in pelvic floor dysfunction, 160
topical therapy, 156–9
anesthetics, 157
benefit of, 156
capsaicin, 157–8
drug trials, 157
estrogen, 158
gabapentin, 158
nitroglycerin, 158
side effects and limitations, 157
testosterone, 158
vulvar vestibectomy, 162
vulvar vestibulitis syndrome (VVS), 1–2
vulvitis, 102–3
vulvodynia, 1–3
vs chronic vulvar pain, 2–3
generalized, 76–80
biofeedback, 79
epidemiology, 76
etiology of, 76–7
history of term, 2
injectable therapies, 79
oral treatments, 78–9
overview of, 76
physical examination of, 77
physical therapy, 79
psychological aspects, 79–80
topical treatment, 77–8
history of, 1
major subtypes, 2
provoked vestibulodynia, 1
and sexual abuse, 215
treatment of, 150–53
acupuncture, 153
biofeedback, 153
cognitive behavioral therapy, 150–53
hypnosis, 153
pelvic floor rehabilitation, 150–53
psychotherapy, 150–53
vulvodynia research, 255–9
basic research, 258
comorbidity studies, 258
diagnostic categories, 255, 258–9
epidemiological research, 256
fibroblast cell culture, 259
laser-evoked potentials, 258
QST profiling, 258
random controlled trials, 256–8
sexual dysfunction and relationships, 258
treatment, 259
The Vulvodynia Survival Guide (book), 253
vulvovaginal candidiasis, 99–102
clinical features of, 100–101
diagnosis of, 101
epidemiology, 99
host factors, 100
management of, 101
pathogenesis of, 100
treatment of, 101–2
vulvovaginitis, 95–103
bacterial vaginosis, 95–8
complications of, 97t
differential diagnosis of, 96t
and dyspareunia, 95
noninfectious, 102–3
trichomoniasis, 98–9
wet mount and cultures, 19
white blood cells (WBCs), 19
Wolffian duct, 119
Xylocaine, 78
yeast-induced sensitization to touch (YIST), 204